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OBJECTIVE: The toxicity of anti-cancer chemotherapeutic agents can be reduced by associating these
compounds, such as the anti-proliferative agent paclitaxel, with a cholesterol-rich nanoemulsion (LDE) that
mimics the lipid composition of low-density lipoprotein (LDL). When injected into circulation, the LDE
concentrates the carried drugs in neoplastic tissues and atherosclerotic lesions. In rabbits, atherosclerotic lesion
size was reduced by 65% following LDE-paclitaxel treatment. The current study aimed to test the effectiveness
of LDE-paclitaxel on inpatients with aortic atherosclerosis.
METHODS: This study tested a 175 mg/m2 body surface area dose of LDE-paclitaxel (intravenous administration,
3/3 weeks for 6 cycles) in patients with aortic atherosclerosis who were aged between 69 and 86 yrs. A control
group of 9 untreated patients with aortic atherosclerosis (72-83 yrs) was also observed.
RESULTS: The LDE-paclitaxel treatment elicited no important clinical or laboratory toxicities. Images were
acquired via multiple detector computer tomography angiography (64-slice scanner) before treatment and at
1-2 months after treatment. The images showed that the mean plaque volume in the aortic artery wall was
reduced in 4 of the 8 patients, while in 3 patients it remained unchanged and in one patient it increased. In the
control group, images were acquired twice with an interval of 6-8 months. None of the patients in this group
exhibited a reduction in plaque volume; in contrast, the plaque volume increased in three patients and
remained stable in four patients. During the study period, one death unrelated to the treatment occurred in the
LDE-paclitaxel group and one death occurred in the control group.
CONCLUSION: Treatment with LDE-paclitaxel was tolerated by patients with cardiovascular disease and showed
the potential to reduce atherosclerotic lesion size.
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’ INTRODUCTION
Severe atherosclerotic aortic disease is a life-threatening
condition that markedly increases the risks of thromboem-
bolic accidents such as stroke, acute myocardial infarction
and obstruction of peripheral vessels, especially in elderly
subjects with large, complex lesions (1,2). In this setting, the
use of non-invasive energetic treatments to reduce lesion size
and inflammation is essential for the prevention of sub-
sequent cardiovascular events.
The most potent anti-proliferative drugs currently avail-
able are chemotherapeutic agents used for cancer treatment.
However, the systemic use of these drugs at high doses for
the treatment of atherosclerotic cardiovascular diseases (3) is
unlikely due to their significant, often life-threatening
toxicity. Nonetheless, the toxicity of such agents can be
strongly diminished by the use of optimized drug-delivery
systems. In a pioneer study performed on patients with acute
leukemia, Maranhão et al. (4) reported the potential of a
cholesterol-rich non-protein nanoemulsion (LDE) as a drug
targeting agent. LDE particles have lipid compositions and
structures that resemble low-density lipoprotein (LDL) and
can be injected directly into the bloodstream. When LDE
particles come into contact with plasma, they acquire
exchangeable apolipoproteins from native lipoproteins, such
as apolipoprotein (apo) E, which binds the particles to LDL
receptors (5). In neoplastic cells, lipoprotein receptors are
overexpressed (6), such that uptake of native LDL and ofDOI: 10.6061/clinics/2016(08)05
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LDE particles is increased relative to that in normal tissues.
It was also shown that the uptake of LDE particles by the
aortas of cholesterol-fed rabbits is increased in comparison
to normal aortas (7) and that rabbit-grafted hearts take up
the nanoemulsion at amounts fourfold greater than native
hearts (8).
When tested in mice by measuring classical pharmacolo-
gical parameters, the toxicity of paclitaxel was markedly
reduced upon association of the drug with LDE particles.
The LD50 of LDE-paclitaxel was tenfold higher than that of a
commercial preparation that uses Cremophor EL as a drug
delivery vehicle (9). Subsequently, patients with advanced
solid cancers treated with LDE-paclitaxel at the high doses
used in clinical practice did not show significant clinical or
laboratory toxicity (10).
LDE-paclitaxel treatment of rabbits induced to exhibit
atherosclerosis via high cholesterol intake resulted in a
65% reduction in lesion size (7). In rabbits that underwent
heterotopic heart transplantation, LDE-paclitaxel treatment
markedly reduced heart graft damage by preventing
coronary vessel destruction and macrophage invasion into
the myocardium (8).
The low toxicity of LDE-paclitaxel shown in cancer
patients (10) and the convincing anti-atherosclerotic effects
of this preparation on the aortic lesions of cholesterol-fed
rabbits (7) prompted us to design the current pilot clinical
study. The aim of this study was to investigate whether
patients with aortic atherosclerotic disease showed good
tolerability to high-dose LDE-paclitaxel treatment and
whether this formulation could achieve reductions in plaque
area that could be documented using a non-invasive,
angiotomography-based approach. To the best of our knowl-
edge, this is the first study in which patients with
cardiovascular disease were treated with a systemic che-
motherapeutic scheme used for cancer treatment.
’ METHODS
Patients
The study group included consecutive patients referred for
computerized tomography of the aorta at the Cardiovascular
Computed Tomography Section of Dante Pazzanese Cardi-
ology Institute in the city of São Paulo and at the Diagnosis
Center of the Paraná Hospital in the city of Maringá. The
recruited patients were on clinical follow-up due to aortic
disease. The inclusion was a diagnosis of severe aortic
atherosclerosis (plaque thickness 44 mm) by multidetector
computed tomography (MDCT) angiography. Ten volunteers
were enrolled in the study for treatment with LDE-paclitaxel.
Seven of the volunteers were male and three were female.
They ranged in age from 69 to 86 years and all showed aortic
dilations and ulcers on angiography. All had systemic
arterial hypertension, 7 had type 2 diabetes mellitus, 3 had
dyslipidemia and 3 were ex-smokers. All were using statins.
A control group (without LDE-paclitaxel treatment) of
nine consecutive volunteer patients composed of 8 men and
one woman aged 72-84 years with severe aortic athero-
sclerosis diagnosed by MDCT angiography was also studied.
All had systemic arterial hypertension and dyslipidemia,
4 had type 2 diabetes mellitus and 5 were ex-smokers. All
were using statins.
Patients with renal dysfunction defined as creatinine
clearance o60 mL/min, or with aortic dissection were
excluded from both groups. The study protocol was
approved by the medical ethics committees of the Dante
Pazzanese Cardiology Institute and Paraná Hospital and all
participants provided informed written consent.
Preparation of LDE particles containing
paclitaxel oleate
LDE particles containing paclitaxel oleate were prepared
by high-pressure homogenization from a pre-emulsion
obtained by ultrasonic irradiation until complete drug
dissolution, according to previously described methods
(11). After the homogenization cycles, the formed emulsion
was centrifuged, sterilized by passage through a 0.22-mm
pore polycarbonate filter (Millipore, Billerica, MA) and kept
at 4oC until use. The final concentration of paclitaxel oleate
LDE particles was confirmed by high-performance liquid
chromatography (Shimadzu, Columbia, ML), which indi-
cated a yield of association of paclitaxel oleate to the LDE
particles of 495%. Based on measurements made by a laser
scattering technique (12), the average particle diameter was
52 nm.
Treatment of patients with LDE-paclitaxel particles
Administration of the treatment commenced at approxi-
mately 10:00 a.m. The patients were infused via the brachial
vein over an approximate 90-min time course with 175 mg/m2
LDE-paclitaxel dissolved in a 0.9% saline solution to a
total volume of 250 ml. The patients were clinically
monitored for adverse reactions during the infusion and
for 1 hour after the procedure. The treatment was adminis-
tered every 3 weeks for a total of 6 cycles. Clinical and
laboratory evaluations were performed 2 weeks after each
cycle and the patients could contact the researchers anytime
to report symptoms. Toxicity ratings based on NCI Common
Toxicity Criteria were assessed before each treatment cycle
and treatment was delayed or suspended if a patient
experienced serious adverse reactions or if significant
laboratory changes were detected. The evaluated laboratory
parameters included red and white blood cell counts, platelet
counts, electrolytes, cholesterol, triglycerides, apolipopro-
teins A-I and B, C-reactive protein, liver and renal function
and coagulation tests.
Imaging studies
In the group of patients treated with LDE-paclitaxel,
MDCT angiography was performed before treatment initia-
tion and again 1-2 months after the last treatment cycle. In
the control group of patients, MDCT angiography was
performed twice with an interval of 6-8 months.
Images were acquired using a 64-slice MDCT scanner
(Aquilion 64; Toshiba Medical Systems, Otawara, Japan),
which is a 64x0.5 mm collimation scanner with a gantry
rotation speed of 400 ms/rotation. Scanning was performed
at 100 kV and 400-500. Depending on each patient’s body
mass index (BMI), the table feed was 6.4 mm/gantry rotation
with a beam pitch of 0.2. For thoracic aorta scans, a
retrospective electrocardiogram (ECG)-gated protocol with
dose modulation was adopted; abdominal aorta scans
were performed using a non-gated protocol. The patients
received 100 ml intravenous iodinated contrast (iopamidol
370 mg/dl) or a maximum dose of 2 ml/kg.
Atherosclerotic plaques were quantified along the aorta by
planimetry performed on 1-mm-thick axial images from pre-
and post-treatment scans, such that an exact comparison of
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the plaque measurements before and after treatment could
be performed. Plaque volume was independently quantified
by two trained imaging technicians who were blinded to
whether the images were taken pre- or post-treatment.
Variations in the measurements of plaque volume between
pre- and post-treatment were considered accurate wheno3%.
Statistical analysis
Bland-Altman analysis was performed using Prism 6
GraphPad software (San Diego, CA) to verify that agreement
existed in the plaque volume measurements taken by the
two observers. The differences between the pre- and post-
treatment values of plaque volume were compared using a
paired Student’s t test. Results were considered significant at
the o0.05 level.
’ RESULTS
A total of 59 treatment cycles were performed and
analyzed with respect to toxicity parameters. Eight patients
completed the 6 scheduled treatment cycles without showing
appreciable clinical or laboratory toxicity. A 78-year-old male
patient experienced sudden death after the fifth treatment
cycle. The patient had high cardiovascular risk and was
found in his home under cardiopulmonary arrest and
transported to the nearest hospital where his death was
registered. Necropsy was not performed due to family
refusal. This patient had not shown any clinical or laboratory
toxicities at any point during the treatment period, and his
death was probably unrelated to the intervention. Another
patient did not return for the post-treatment angiography
within the pre-established period of 1-2 months after the last
(6th) treatment cycle.
None of the patients showed any common toxicities
associated with taxane use, i.e., myelosuppression, nausea,
vomiting, alopecia, arthralgia, myalgia or peripheral neuro-
pathy, or any other toxicities (Table 1). Mild leukopenia
(white blood cell o4300/ml) was observed after the second
and sixth cycles in one patient who remained asymptomatic.
Isolated elevation of alkaline phosphatase (AP) and gamma-
glutamyl transpeptidase (GGT) was found in one patient
throughout the treatment. This patient’s baseline levels of AP
and GGTwere already elevated at study entry and increased
by 1.5- and 4-fold, respectively. Bilirubin, AST and ALT
levels; coagulation test results; and liver ultrasound
remained normal in all patients throughout the treatment
period. Mild alterations in renal function that did not require
intervention were observed in up to 3 patients after
treatment cycles 1, 2, 3, 5 and 6 (Table 1).
Total, LDL and HDL cholesterol, triglycerides and
apolipoprotein A1 and B concentrations did not significantly
change during the treatment cycles (Table 2).
Table 3 displays the individual data on aortic wall
thickness volume of the eight patients in whom pre- and
post-treatment angiographic exams were performed, as
measured by the two blinded observers. Bland-Altman
analysis showed that there was a strong correlation between
the plaque volume measurements of the two observers, with
ao3% variation. After treatment with LDE-paclitaxel, plaque
volume was reduced by43% in four patients (patients 1, 4, 5
and 7), remained stable in two patients (patients 3 and 8) and
increased by 43% in two patients (patients 2 and 6).
Table 1 - Toxicity of LDE-paclitaxel administered as an intravenous
infusion over 2 h every 3 weeks to 10 patients with aortic
atheroma at a dose of 175 mg/m2. Toxicity was classified from
grade 1 (mild; asymptomatic or mild symptoms; clinical or diagnostic
observations only; intervention not indicated) to grade 5 (death
related to adverse event). The data represent the number of patients
who presented grade 1 toxicity only because no grade 2-5 toxicities
were observed.
Treatment cycles 1 2 3 4 5 6
Grade 1 toxicity
Clinical
Nausea 0 0 0 0 0 0
Vomiting 0 0 0 0 0 0
Local pain 0 0 0 0 0 0
Arrhythmia 0 0 0 0 0 0
Fever 0 0 0 0 0 0
Dyspnea 0 0 0 0 0 0
Alopecia 0 0 0 0 0 0
Hematologic
Anemia 0 0 0 0 0 0
Leucopenia 0 1 0 0 0 1
Thrombocytopenia 0 0 0 0 0 0
Hepatic
AST 0 0 0 0 0 0
ALT 0 0 0 0 0 0
Bilirubin 0 0 0 0 0 0
AP 1 1 1 1 1 1
GGT 1 1 1 1 1 1
Renal
Urea 2 2 1 0 1 0
Creatinine 0 3 2 0 0 1
AST: aspartate aminotransferase; ALT: alanine aminotransferase;
AP: alkaline phosphatase; GGT: gamma-glutamyl transferase
Table 2 - Fasting serum lipids and apolipoproteins (in mg/dl) in the patients treated with LDE-paclitaxel, measured approximately
2 weeks after each treatment cycle (the results are shown as the mean±S.D.). Paclitaxel-LDE was administered via intravenous infusion
every 3 weeks at a dose of 175 mg/m2 body surface area.
Treatment Cycles
Parameters 0 1 2 3 4 5 6
Cholesterol (mg/dL)
Total 167±44 169±32 169±30 168±24 165±28 173±34 204±48
LDL 90±34 90±15 86±14 92±18 87±18 92±22 109±34
HDL 45±14 46±13 49±13 48±14 46±11 47±13 49±12
Triglycerides (mg/dL) 170±93 161±105 124±46 147±56 134±58 156±72 204±76
Apolipoproteins (mg/dL)
A1 136±19 127±24 131±21 131±9 136±25 136±20 155±20
B 92±30 86±15 86±19 87±20 84±18 89±23 99±38
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However, the differences between the pre- and post-treatment
values were not significant (p=0.348).
In Table 4, the plaque volume data obtained from the non-
treated control patients at 6-8 month intervals are shown. In
this group of nine patients, no one showed a decrease in
plaque volume over the period between the first and the last
observation. In 6 patients, the plaque volumes were stable
and in 3 there was a 43% increase in plaque volume.
Comparing the data from the non-treated group, there was a
statistically significant increase in plaque volume from the
first to the second exam (po0.05).
’ DISCUSSION
Aortic atheroma is a manifestation of systemic athero-
sclerosis in which the presence of aortic plaques is associated
with the presence of carotid artery or coronary artery
plaques. Thus, the identification of aortic atheromas is a
strong predictive risk factor for major cardiovascular events,
such as stroke or acute myocardial infarction (13,14). In this
context, the risk factors for aortic atheroma are similar to
those for coronary or cerebrovascular artery atherosclerotic
disease, namely, older age and male gender, smoking,
hypercholesterolemia, hypertension and diabetes (15).
Patients with aortic atherosclerotic disease also seem to
benefit from statin use (16).
A 175 mg/m2 body surface area paclitaxel dose was
tested in the patients with aortic atheroma, which is equal to
that used in cancer chemotherapy schemes. Paclitaxel is a
major drug in cancer chemotherapy and is also used in
pharmacological stents to inhibit restenosis. The mechanism
of action for the drug is based on the ability of taxanes to
increase tubulin polymerization into stable microtubules.
It also promotes microtubule stabilization, thus preventing
depolymerization. The overall effect is inhibition of the
mitotic apparatus formation and arrest of mitosis in the
G2/M phase of the cell cycle (17,18).
The toxicity of commercially available paclitaxel, in which
Cremophor EL is used as a drug delivery vehicle, is
cumulative. The main toxicities are hematological, with
neutropenia being the most prominent toxicity of the drug.
Neurotoxicity, arrhythmias and alopecia are other frequent
toxicities elicited by paclitaxel, together with major hyper-
sensitivity reactions related to Cremophor EL.
The fact that the toxicity of commercial paclitaxel is
cumulative and that paclitaxel-associated LDE particles were
administered here at a dose roughly twice that used in the
study reported by Margolis et al. (19) for six cycles without
producing appreciable toxicities highlights the superior
tolerability of LDE-paclitaxel. To document this, a total
59 chemotherapy cycles were analyzed and the results
confirmed the absence of the significant toxicities previously
shown in cancer patients. This reduced toxicity can be
ascribed to several factors, such as the unique biodistribution
pattern created by the carrier, the envelopment of the drug in
circulation, which diminishes contact with normal tissues
and organs and the increased half-life of the drug.
In a previous study, treatment of rabbits harboring
atherosclerotic lesions induced by high cholesterol consump-
tion with LDE-paclitaxel markedly decreased macrophage
and smooth muscle cell invasion of the intima, as well as the
presence of apoptotic cells (7). This accounted for the great
reduction in lesion area and intima width observed in the
aortas of the treated rabbits. In rabbits with heart grafts, the
expression levels of pro-inflammatory factors such as tumor
necrosis factor-a, interleukin-1b, interleukin-18, monocyte
chemotactic protein-1, vascular cell adhesion molecule-1,
matrix metalloproteinase-9, and matrix metalloproteinase-12,
as well as the anti-inflammatory factor interleukin-10, were
strongly up-regulated in the heart grafts of non-treated
animals compared with native hearts (8). Treatment with
LDE-paclitaxel resulted in a several fold reduction of the
gene expression of both pro- and anti-inflammatory factors
in the grafted hearts (20). It is worthwhile to note that similar
results were achieved following the treatment of cholesterol-
fed rabbits with other preparations of chemotherapeutic
agents associated with LDE, such as LDE-etoposide (21) and
LDE-methotrexate (22). Thus, it can be assumed that lesion
size reduction, as was observed in patients 1, 4, 5 and 7 in the
current study, is a consequence not only of the anti-
proliferative actions of the drug but also of the reduction of
inflammation in the lesion area. It is also worth noting that
the inflammatory process increases the actions of protei-
nases, which can result in plaque rupture and hemorrhage,
thrombus formation and thromboembolic accidents.
The large caliber and thickness of the aortic vessel
facilitates the quantification of lesion volumes using MDCT,
which is non-invasive. The reliability of the quantitative
analyses that were independently made by the two blinded
imaging technicians was confirmed by the o3% inter-
observer variability. Although the study was limited by the
sample containing only eight patients, it is noteworthy that
four of the patients showed a regression in aortic plaque
volume, whereas none of the patients in the non-treated
Table 3 - Aortic plaque volumes in 8 patients with aortic
atherosclerotic disease before and after six cycles of treatment
with LDE-paclitaxel administered via intravenous infusion over
2h every three weeks at a 175 mg/m2 body surface area dose.
Plaque Volume (cm3)
Patient Pre-treatment Post-treatment % Variation
1 367 288 -22
2 819 851 +4
3 627 641 +2
4 793 572 -28
5 530 477 -10
6 457 530 +16
7 398 377 -5
8 257 256 0
Table 4 - Plaque volume (cm3) measured twice in the aorta with
a 6-8 month interval between the two observations in 9 patients
with aortic atherosclerotic disease who were not treated with
LDE-paclitaxel (controls).
Plaque Volume (cm3)
Patient 1st Observation 2nd Observation % Variation
9 202 204 +2
10 358 363 +2
11 133 136 +2
12 272 280 +3
13 382 398 +4
14 538 552 +3
15 138 142 +3
16 190 201 +6
17 392 406 +4
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control group showed a regression in lesion size. Addition-
ally, although there was no significant reduction in plaque
volume in the LDE-paclitaxel group after treatment, in the
control group, probably due to the small number of patients,
there was an increase in plaque volume, suggesting disease
progression in these patients.
With respect to the data on plasma lipid and apolipoprotein
concentrations collected during the study, the lack of observed
effect following the LDE-paclitaxel treatment was expected
because paclitaxel does not interfere with plasma lipid
metabolism. Indeed, the natural history of aortic atheroma is
not always progressive; rather, a slow progression in plaque
thickness is the most common clinical course (1,2).
This pilot study showed that treatment with high-dose
LDE-paclitaxel had low enough toxicity to permit its use in
patients with cardiovascular disease. Although not statisti-
cally significant, there was an average 18% reduction in
plaque volume in four out of the eight participants, which is
a promising finding. This result was especially noteworthy in
view of the short 18-week treatment period and when
considering that plaque reduction did not occur in any of the
control group patients. In contrast, statistically significant
disease progression was observed in the non-treated control
patients. The results of the current study are supportive for
future trials aiming to confirm the efficacy of this novel
treatment in a large number of participants.
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